Vol. 5, Issue 9 (2016)
Formulation and In-vitro evaluation of mucoadhesive nanospheres for an alpha glucosidase inhibitor
Agilandeswari D, Atefeh Shabani, Ayesha Syed, Mohan Maruga Raja M K and Jesindha Beyatricks K
The aim of this study was to formulate and evaluate the release of Mucoadhesive nanosphere of Miglitol (half-life 2 hours) for the treatment of diabetes type 2 by combine the potential advantages of Mucoadhesive with controlled drug delivery using various ratios of different polymers. The results of this investigation indicate that ionic cross linking technique Ionotropic gelation method can be successfully employed to fabricate Miglitol nanosphere. The technique provides characteristic advantage over conventional nanosphere method, which involves an “all-aqueous” system, avoids residual solvents in nanospheres. FT-IR spectra of the physical mixture revealed that the drug is compatible with the polymers and copolymers used. The mean particle size of the prepared nanosphere was in the size range of 512.1±0.2to 903.6±0.4nm and is suitable for bioadhesive nanospheres for oral administration. Increase in the polymer concentration led to increase in % yield, % drug entrapment efficiency, particle size, % swelling and % mucoadhesion. The in-vitro mucoadhesive study demonstrated that nanosphere of Miglitol using sodium alginate along with Carbopol 934 as copolymer adhered to the mucus to a greater extent than the nanospheres of Miglitol using sodium alginate along with Carbopol 971 and HPMC K4M as copolymers. Analysis of drug release mechanism showed that the drug release from the formulations followed non-fickian diffusion and the best fit model was found to be Korsmeyer-Peppas. Based on the results of evaluation tests formulation coded T4 was concluded as best formulation.
How to cite this article:
Agilandeswari D, Atefeh Shabani, Ayesha Syed, Mohan Maruga Raja M K and Jesindha Beyatricks K. Formulation and In-vitro evaluation of mucoadhesive nanospheres for an alpha glucosidase inhibitor. 2016; 5(9): 123-130.